Fluorescent humanized anti-CEA antibody specifically labels metastatic pancreatic cancer in a patient-derived orthotopic xenograft (PDOX) mouse model

Pancreatic cancer is a highly lethal disease in part due to incomplete tumor resection. Targeting by tumor-specific antibodies conjugated with a fluorescent label can result in selective labeling of cancer for surgical navigation. In the present study, we describe a patient-derived orthotopic xenogr...

Full description

Saved in:
Bibliographic Details
Published in:Oncotarget 2018-12, Vol.9 (99), p.37333-37342
Main Authors: Lwin, Thinzar M, Miyake, Kentaro, Murakami, Takashi, DeLong, Jonathan C, Amirfakhri, Siamak, Filemoni, Filemoni, Yoon, Sang Nam, Yazaki, Paul J, Shivley, John E, Datnow, Brian, Clary, Bryan M, Hoffman, Robert M, Bouvet, Michael
Format: Article
Language:English
Subjects:
Research Paper
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Pancreatic cancer is a highly lethal disease in part due to incomplete tumor resection. Targeting by tumor-specific antibodies conjugated with a fluorescent label can result in selective labeling of cancer for surgical navigation. In the present study, we describe a patient-derived orthotopic xenograft model of pancreatic cancer that recapitulated the disease on a gross and microscopic level, along with physiologic clinical manifestations. We additionally show that the use of an anti-CEA antibody conjugated to the near-infrared (NIR) fluorescent dye, IRDye800CW, can selectively highlight the pancreatic cancer and its metastases in this model with a tumor-to-background ratio of 3.5 (SEM 0.9). The present results demonstrate the clinical potential of this labeling technique for fluorescence-guided surgery of pancreatic cancer.
ISSN:1949-2553
1949-2553
DOI:10.18632/oncotarget.26484